Our results indicate that the SNV rs2853669 has potential as a prognostic marker of survival in AML, in addition to the clinically used biomarkers FLT3-ITD, NPM1 and CEBPA mutations, which may further aid in treatment decisions such as allocation of patients to early stem cell transplantation. This evidence concerns the gene NPM1 and acute myeloid leukemia.